Navigation Links
BioWa Licenses POTELLIGENT(R) Technology to GlaxoSmithKline for Use in Antibody Development and Commercialization

PRINCETON, N.J., Dec. 8 /PRNewswire/ -- BioWa, Inc., announced today that it licensed to GlaxoSmithKline (NYSE: GSK) its POTELLIGENT(R) Technology for use in developing and commercializing select GSK antibodies with enhancement of antibody-dependent cellular cytotoxicity (ADCC).

"GSK is recognized as a key player in the field of antibody drug discovery," said Dr. Masamichi Koike, BioWa President and CEO. "We believe this represents an important opportunity to promote the development of more effective targeted treatments for debilitating diseases where enhanced ADCC might offer a significant therapeutic benefit."

Under the terms of the agreement, BioWa will provide GSK with non- exclusive commercial rights to use the technology for multiple antibodies. In return, BioWa will receive technology access fees, and may receive milestone payments and royalties from resulting products which are developed by GSK. Additional terms were not disclosed.

About POTELLIGENT(R) Technology

POTELLIGENT(R) Technology improves potency and efficacy of antibody therapeutics, by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics. POTELLIGENT(R) Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell. Research shows that POTELLIGENT(R) Technology dramatically enhances ADCC activity of an antibody in vitro, and significantly increases potency and efficacy of the antibody in vivo. A number of POTELLIGENT(R) antibodies are being investigated in human clinical trials.

About BioWa, Inc.

BioWa is a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd., Japan's leading pharmaceutical and largest biotech company, and is the exclusive worldwide licensor of AccretaMab(TM) platform. AccretaMab(TM) platform consists of POTELLIGENT(R) and COMPLEGENT(TM) Technologies, creating a superior antibody molecule with enhanced ADCC and CDC activities. BioWa is offering POTELLIGENT(R) and COMPLEGENT(TM) Technologies to partners under a license to maximize the value of these technologies. Together with Kyowa Hakko Kirin, BioWa is focused on development of ADCC/CDC enhanced monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases. For more information about BioWa, visit its web site at

POTELLIGENT(R), COMPLEGENT(TM), and AccretaMab(TM) are the trademarks of Kyowa Hakko Kirin Co., Ltd. All rights are reserved.

SOURCE BioWa, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
2. BioWa Announces Expansion of License Agreement with Genentech for BioWas POTELLIGENT(R) Technology
3. Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines
4. BioWa and Medarex Announce License of BioWas COMPLEGENT(TM) Technology
5. BioWa Announces License of Biowas Potelligent(R) Technology to KaloBios Pharmaceuticals
6. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
7. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
8. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
9. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
10. Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals
11. Protherics Licenses its CoVaccine HT Adjuvant to Nobilon for Influenza Vaccine Indications
Post Your Comments:
(Date:6/23/2016)... Prairie, WI (PRWEB) , ... June 23, 2016 ... ... consultancy focused on quality, regulatory and technical consulting, provides a free webinar ... is presented on July 13, 2016 at 12pm CT at no charge. , ...
(Date:6/23/2016)... 22, 2016  Amgen (NASDAQ: AMGN ) ... QB3@953 life sciences incubator to accelerate the development ... laboratory space at QB3@953 was created to help high-potential ... for many early stage organizations - access to laboratory ... Amgen launched two "Amgen Golden Ticket" awards, providing each ...
(Date:6/22/2016)... , June 22, 2016 Cell ... will allow them to produce up to one ... one lot within one week. These high-quality, consistent ... laboriously preparing cells and spend more time doing ... through a proprietary, high-volume manufacturing process that produces ...
(Date:6/22/2016)... YORK , June 22, 2016  According ... growing next generation sequencing (NGS) market include significant ... of smaller sequencers.  More accessible and affordable sequencers, ... to growing demand for consumables including sample prep ... The Market for Sample Preparation for Next Generation ...
Breaking Biology Technology:
(Date:6/22/2016)... -- On Monday, the Department of Homeland Security (DHS) ... for the Biometric Exit Program. The Request for Information ... explains that CBP intends to add biometrics to confirm ... States , in order to deter visa overstays, ... Logo - ...
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
Breaking Biology News(10 mins):